Abstract
Palmar-plantar erythrodysesthesia, also known as hand-foot syndrome (HFS), is a common dermatologic toxicity of capecitabine. In this report, the case of a 59-year-old man with metastatic pancreatic ductal adenocarcinoma who developed grade 2 HFS with rare genital involvement is described. This case underscores the importance of recognizing atypical genital involvement in HFS to support timely management.
References
Chan, B. L., & Wang, T. (2024). Capecitabine-induced genital hand–foot syndrome treated with topical tacrolimus. Cureus, 16(4), e57570. https://doi.org/10.7759/cureus.57570
Cytotoxics and antimetabolites. (n.d.). McGraw Hill Medical. https://accessmedicine-mhmedical-com.foyer.swmed.edu/content.aspx?sectionid=269730494&bookid=3191
FDA. (2015a). XELODA (capecitabine) tablets, for oral use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf
FDA. (2015b). FARYDAK (panobinostat) capsules, for oral use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205353s000lbl.pdf
FDA. (2018). ZOLINZA® (vorinostat) capsules, for oral use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021991s009lbl.pdf
Fountzilas, C., Borazanci, E. H., Shields, A. F., D’Olimpio, J. T., Hecht, J. R., Tang, S.-C., Michelson, G., Liganor, L., Cho, S. A., & Ko, A. H. (2024). Results of the safety and tolerability of ivaltinostat plus capecitabine in the phase 1b portion of a phase 1b/2, dose-escalation, randomized, multicenter study in the maintenance setting in patients with metastatic pancreatic adenocarcinoma. Journal of Clinical Oncology, 42(number 3 suppl), 666(2024). https://doi.org/10.1200/JCO.2024.42.3_suppl.666
Gressett, S. M., Stanford, B. L., & Hardwicke, F. (2006). Management of hand–foot syndrome induced by capecitabine. Journal of Oncology Pharmacy Practice, 12(3), 131–141. https://doi.org/10.1177/1078155206069242
Hu, H., Corkum, M. T., & Perera, F. (2018). Palmar–plantar erythrodysesthesia with genital involvement secondary to capecitabine chemoradiotherapy: A case report. Cureus, 10(12), e3704. https://doi.org/10.7759/cureus.3704
Lou, Y., Wang, Q., Zheng, J., Hu, H., Liu, L., Hong, D., & Zeng, S. (2016). Possible pathways of capecitabine-induced hand–foot syndrome. Chemical Research in Toxicology, 29(10), 1591–1601. https://doi.org/10.1021/acs.chemrestox.6b00215
Marks, P. A. (2010). Histone deacetylase inhibitors: A chemical genetics approach to understanding cellular functions. Biochimica et Biophysica Acta, 1799(10–12), 717–725. https://doi.org/10.1016/j.bbagrm.2010.05.008
National Cancer Institute. (2017). Common Terminology Criteria for Adverse Events (CTCAE). https://dctd.cancer.gov/research/ctep-trials/for-sites/adverse-events/ctcae-v6.pdf
National Comprehensive Cancer Network. (2021). NCCN Clinical Practice Guidelines in Oncology:. Pancreatic adenocarcinoma, version 2.2021. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf
Nikolaou, V., Syrigos, K., & Saif, M. W. (2016). Incidence and implications of chemotherapy-related hand–foot syndrome. Expert Opinion on Drug Safety, 15(12), 1625–1633. https://doi.org/10.1080/14740338.2016.1238067
Sim, W., Lim, W.-M., Hii, L.-W., Leong, C.-O., & Mai, C.-W. (2022). Targeting pancreatic cancer immune evasion by inhibiting histone deacetylases. World Journal of Gastroenterology, 28(18), 1934–1945. https://doi.org/10.3748/wjg.v28.i18.1934
Walker, E. J., & Ko, A. H. (2023). Maintenance treatment for metastatic pancreatic cancer: Balancing therapeutic intensity with tolerable toxicity. Cancers, 15(14), 3657. https://doi.org/10.3390/cancers15143657
